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1066Up-Regulation of a4b7 Integrin on Peripheral T Cell
Subsets Correlates with the Development of Acute
Intestinal Graft-versus-Host Disease following
Allogeneic Stem Cell Transplantation
Yi-Bin Chen,1 Haesook T. Kim,2 Sean McDonough,3 Robert D. Odze,4 Xiaopan Yao,2
Suzan Lazo-Kallanian,3 Thomas R. Spitzer,1 Robert Soiffer,3 Joseph H. Antin,3 Jerome Ritz3,5Acute graft-versus-host disease (aGVHD) is a major complication after hematopoietic stem cell transplan-
tation (HSCT). The pathophysiology of aGVHD involves priming of naı¨ve donor T cells in host secondary
lymphoid tissue, followed by migration of effector T cells to target organs. Mediators of lymphocyte traffick-
ing are believed to play a significant role in this migration. In this retrospective case-controlled study, we
analyzed the expression of a4b7 integrin and CCR9, 2 surface T cell molecules specific for intestinal traffick-
ing, from blood samples collected previously from 59 patients after HSCT (20 without aGVHD, 20 with skin
aGVHD, and 19 with intestinal aGVHD). All samples had been obtained before the onset of aGVHD symp-
toms (with 1 sample collected on the day of symptom onset). Analysis by flow cytometry demonstrated that
a4b7 integrin was significantly increased on both naı¨ve and memory T cells in patients who subsequently
developed intestinal aGVHD, with the most significant differences observed in memory subsets. Immunohis-
tochemical staining on rectal biopsy specimens from patients with intestinal aGVHD showed that expression
of a4b7 integrin was concentrated on mononuclear cells in blood vessels within the intestinal mucosa. These
results suggest that a4b7 integrin likely is involved in lymphocyte trafficking in intestinal aGVHD and may
have potential clinical use as a correlative biomarker or as a target for the treatment and prophylaxis of
intestinal aGVHD after HSCT.
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Acute graft-versus-host-disease (aGVHD) is a ma-
jor cause of morbidity and mortality after allogeneic
hematopoietic stem cell transplantation (HSCT) [1].
It is caused by the recognition of host antigens by do-
nor lymphocytes, with target organ damage mediated
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tissue, the gastrointestinal (GI) tract is not only amajor
target organ, but also a crucial amplifier of a systemic
cytokine response in aGVHD [2]. Intestinal aGVHD
is believed to be similar to other immunologic re-
sponses in that it has similar requirements for lympho-
cyte trafficking. Priming and maturation of naı¨ve
donor T cells that are targeted for the gut mucosa
are believed to be mediated by activated host dendritic
cells within gut-associated secondary lymphoid tissue
(GALT), including Peyer’s patches (PPs) of the small
intestine, the appendix, and mesenteric lymph nodes
[3]. Recent evidence has suggested that effector T cells
acquire an intestinal homing phenotype through inter-
actions with GALT dendritic cells in a process medi-
ated by retinoic acid [4-8]. Once T cells have been
educated in GALT through antigen engagement and
costimulation, they continue to circulate through the
bloodstream, but preferentially migrate to intestinal
effector sites—the lamina propria and epithelium of
the small and large intestine—as directed by their spe-
cific surface molecules [9,10]. This process of specific
lymphocyte trafficking represents a potentially novel
Biol Blood Marrow Transplant 15:1066-1076, 2009 1067a4b7 Integrin and Intestinal GVHDtarget for the monitoring, treatment, and prophylaxis
of intestinal aGVHD.
Several classes of membrane surface molecules, in-
cluding selectins, integrins, chemokine receptors, and
pertussis-sensitive G-proteins, are involved in lym-
phocyte trafficking; all of these help ensure organ-
specific localization of lymphocytes [11-13]. One
specific molecule, a4b7 integrin, plays a crucial role
in the recirculation of naı¨ve T cells to intestinal sec-
ondary lymphoid tissue, as well as the selective traffick-
ing of specific effector T cells into sites of intestinal
inflammation [14-16]. The primary ligand for a4b7 in-
tegrin is mucosal addressin cell adhesion molecule 1
(MAdCAM-1), which is selectively expressed in the
high endothelial venules and follicular dendritic cells
of GALT, with specific up-regulation at sites of active
inflammation [17-20]. Chemokines are thought to par-
ticipate in this process through the activation of a4b7
integrin [21-23]. Although the precise chemokines
in this process involved are unknown, the CCR9–
CCL25 interaction has emerged as a good candidate
[24,25]. CCL25 (TECK) has been shown to be ex-
pressed only in epithelial cells of the thymus and small
intestine [26], and the vast majority of CCR9-
expressing T cells in the peripheral blood express
a4b7 integrin as well [27].
In the present study, we analyzed peripheral blood
(PB) samples collected previously from 59 human
patients after HSCT, to assess the involvement of
a4b7 integrin and CCR9 in lymphocyte trafficking in
intestinal aGVHD. We analyzed the expression of
a4b7 integrin and CCR9 on specific T cell subsets
by flow cytometry. a4b7 integrin was found to be sig-
nificantly up-regulated on both naı¨ve and memory T
cell subsets in patients who subsequently developed in-
testinal aGVHD compared with those who developed
primarily cutaneous aGVHD or did not develop
aGVHD. Immunohistochemical staining on previ-
ously obtained rectal biopsy specimens in patients
with intestinal aGVHD showed the presence of a4b7
integrin on inflammatory mononuclear cells aggre-
gated within mucosal blood vessels. Our findings sug-
gest that a4b7 integrin is up-regulated on peripheral
blood T cells before the onset of symptomatic intesti-
nal aGVHD, implying a role for this molecule in the
pathophysiology of aGVHD.METHODS
Patients and Samples
This was a retrospective case-controlled analysis
using patient samples identified from the stem cell
transplantation database at the Dana-Farber Cancer
Institute (DFCI). The study design was approved by
the Institutional Review Board of the Dana-Farber/
Harvard Cancer Center. Using a random number gen-erator, we selected 59 patients, categorized into 3
groups: control, comprising 20 patients without
aGVHD after HSCT; skin, comprising 20 patients
with primarily cutaneous aGVHD after HSCT (grade
III or IV); and gut, comprising 19 patients with intes-
tinal aGVHD after HSCT (grade III or IV). Patients
in the gut group were allowed to have skin or liver
aGVHD, whereas those in the skin group were not al-
lowed to have greater than grade I disease of the intes-
tine or liver. The diagnosis and grading of aGVHD
were recorded previously and were based on the pa-
tients’ clinical and pathological features, in accordance
with previously published criteria [28]. The patients
had been treated with either myeloablative (MA; either
cyclophosphamide (Cy)/total body irradiation (TBI)
or busulfan (Bu)/Cy) or reduced-intensity conditi-
oning (RIC; Bu/Flu) regimens. Donor stem cells
were obtained from either HLA-matched related do-
nors (MRDs) or HLA-matched unrelated donors
(MUDs). All patients received calcineurin inhibitor–
based (either cyclosporine (CsA) or tacrolimus, dosed
to target serum level) GVHD prophylaxis.
Blood Samples
All of the samples used in this study were obtained
from a patient sample repository established at DFCI
beginning in 2000 and were collected from patients
who had signed informed consent to provide blood
and bone marrow samples for research purposes. All
samples were collected in EDTA tubes from patients
after HSCT, and mononuclear cells were isolated by
density gradient centrifugation. At the time of collec-
tion, cells were cryopreserved in FBS 1 10% DMSO
at 2180C. After appropriate patients were identified,
samples were selected with the goal of using blood
samples that had been collected within 30 days before
the onset of aGVHD symptoms. After the blood sam-
ples were selected, peripheral blood mononuclear
cells (PBMCs) were washed before analysis by flow
cytometry.
Flow Cytometry
Cells were stained using a 7-color antibody panel
comprising conjugated antibodies against CD45,
CD3, CD4, CD8, CD45RO, a4b7 integrin, and
CCR9. All of these reagents were purchased from
Beckman Coulter (Fullerton, CA) except anti-CCR9,
which was purchased from R&D Systems (Minneapo-
lis, MN), and anti-a4b7 integrin (ACT-1), which was
provided by Millennium Pharmaceuticals (Cam-
bridge, MA) and conjugated at DFCI with phycoery-
thrin (PE). The cells were then analyzed using
a Beckman Coulter FC500 or a FACSAria Special Or-
der Research Platform (BD Biosciences, San Jose, CA)
flow cytometer. T cell subsets were defined as follows:
naı¨ve CD41 T cells (CD451, CD31, CD41, and
1068 Biol Blood Marrow Transplant 15:1066-1076, 2009Y.-B. Chen et al.CD45RO-), memory CD41 T cells (CD451, CD31,
CD41, and CD45RO1), naı¨ve CD81 T cells
(CD451, CD31, CD81, and CD45RO-), and memory
CD81 T cells (CD451, CD31, CD81, and
CD45RO1). Flow cytometry results were analyzed us-
ing FlowJo version 7.1.3 (FlowJo,) and CXP Analysis
(Beckman Coulter, Miami, Florida).
Immunohistochemistry
Of the 19 patients in the gut group, 17 had previ-
ously obtained rectal biopsy specimens available for
analysis, all of which revealed aGVHD pathologically.
Conditions were defined for a PE-conjugated ACT-1
and anti-CCR9 antibodies, and immunohistochemical
staining was performed. Sections (4 m thick) of forma-
lin-fixed tissue were used for immunoperoxidase anal-
ysis after baking at 60C for 1 hour, deparaffinization,
and rehydration (100% xylene  4 for 3 minutes each,
100% ethanol 4 for 3 minutes each, and running wa-
ter for 5 minutes). The sections were blocked for per-
oxidase activity with 3% hydrogen peroxide in ethanol
for 15 minutes, and then washed under running water
for 5 minutes. All of the sections were treated in 1 mM
EDTA buffer using a digital decloaking chamber
(Pacific Southwest Lab Equipment, Vista, CA). The
slides were cooled for 15 minutes, and then transferred
to PBS. All of the sections were blocked with 1.5%
horse serum for 15 minutes in a humid chamber at
room temperature. The sections were then incubated
with the corresponding primary antibodies: mouse
monoclonal anti-CCR9 (clone 248621, 1:100 dilution;
R&D Systems) and mouse monoclonal anti–a4b7 in-
tegrin (1:5 dilution; Millennium Pharmaceuticals) for
1 hour. Primary antibodies were detected using Vec-
tastain Elite ABC Kit reagents (Vector Laboratories,
Burlington, CA). The secondary antibody was used
at a 1:200 dilution, made in 2% horse serum, and incu-
bated for 30 minutes. Avidin-biotin complex was incu-
bated for 30 to 40 minutes. The sections were
developed using 3,30-diaminobenzidine (Sigma-
Aldrich, St Louis, MO) as a substrate, and counter-
stained with Gill’s hematoxylin (Fisher Scientific,
Pittsburgh, PA). Images were viewed using a Zeiss
Axiophot microscope equipped with Zeiss Plan Apo
10 and Zeiss Neofluar 40 objectives (Carl Zeiss,
Germany, Carl Zeiss, Inc. Thornwood, NY) and ac-
quired using a SPOT RT color digital camera (Diag-
nostic Instruments, Sterling Heights, MI). Final
images were obtained using SPOT Advanced software
(Diagnostic Instruments, Inc., Sterling Heights, MI).
Statistical Analysis
Two-sided Fisher’s exact, Kruskal-Wallis, and
Wilcoxon rank-sum (WRS) tests were used for com-
parisons of baseline patient and transplant characteris-
tics. The 2-sided exactWRS test was used for pairwisegroup comparisons of each peripheral T cell subset.
To adjust for multiple comparisons, permutation test-
ing was performed using SAS version 9.1.3 PROC
MULTTEST (SAS Institute, Cary, NC), with
10,000 resamples. If the adjusted P value from the per-
mutation test was\.05, then the null hypothesis (of no
association) for that particular T cell subset was re-
jected. In addition, multivariable logistic regression
analysis with a generalized logit function was per-
formed to further assess each T cell subset as a predic-
tive biomarker for intestinal aGVHD in the presence
of known risk factors for aGVHD. All T cell subsets
were log-transformed before logistic regression analy-
sis was performed. Correlation analysis was performed
using Spearman’s correlation test. The recursive parti-
tioning method and receiver operating characteristic
curves (ROCs) were used to identify an optimal cutoff
value for phenotype expression level.RESULTS
Patient and Sample Characteristics
Clinical characteristics of the 59 study patients are
summarized in Table 1. Of these 59 patients, 33 re-
ceived an MA conditioning regimen and 26 received
an RIC regimen before HSCT. All 3 study groups
were similar in terms of age range at the time of trans-
plantation and underlying conditions. Patients re-
ceived stem cells from an MRD, and 40 patients
received stem cells from anMUD.Most of the patients
received peripheral blood stem cells (PBSCs). All 59
patients received calcineurin inhibitor–based (either
CsAor tacrolimus)GVHDprophylaxis with additional
methotrexate (MTX), sirolimus, corticosteroids, or
some combination of these agents. As shown in Table
1, more patients in the control group had received siro-
limus; however, there was no significant difference in
the use of sirolimus between the gut and skin groups
(P5 .51 for sirolimus vs no sirolimus).
PB samples were identified based on their relation-
ship to the onset of aGVHD symptoms. In the study
patients, the timing of onset of aGVHD varied from
day 10 to day 166 after HSCT, with a median time
to development of aGVHD of 36 days after HSCT
(range, 18 to 156 days) in the gut group and 40 days af-
ter HSCT (range, 10 to 166 days) in the skin group (P
5 .70). Most of the samples (89% of samples in the gut
group and 80% of samples in the skin group) were col-
lected within 30 days before the onset of aGVHD
symptoms. With the exception of 1 patient in the gut
group (sample drawn on the day of symptom onset),
all samples were drawn before the manifestation of
any clinical evidence of GVHD, as verified by themed-
ical records. The median time from the date of sample
collection to the onset of aGVHD symptoms was 14
days (range, 0 to 63 days) in the gut group and 8 days
Table 1. Baseline Patient Characteristics
Characteristic
Gut
(n 5 19)
Skin
(n 5 20)
Control
(n 5 20) P
Age, median (range) 44 (18, 68) 53 (18, 66) 46 (19, 65) .33
Time from day of HSCT to
blood sample (day), median
(range)
34 (5, 106) 26 (5, 140) 35 (15, 93) .08
Time from HSCT to onset of
symptomatic aGVHD (day),
median (range)
36 (18, 156) 40 (10, 166) N/A .7
Time from blood sample to
onset of symptomatic
aGVHD (day), median (range)
14 (0, 63) 8.5 (2, 86) N/A .88
Diagnosis .19
ALL 1 (5%) 1 (5%) 3 (15%)
AML/AML from MDS 5 (26%) 6 (30%) 7 (35%)
CLL/PLL 4 (21%) 4 (20%) 1 (5%)
CML 2 (11%) 1 (5%) 3 (15%)
CMML 0 1 (5%) 0
CTCL 0 1 (5%) 0
HD 1 (5%) 1 (5%) 2 (10%)
NHL* 0 1 (5%) 3 (15%)
MDS 6 (32%) 3 (15%) 1 (5%)
MF 0 1 (5%) 0
Donor .37
MRD 5 (26%) 9 (45%) 5 (25%)
MUD 14 (74%) 11 (55%) 15 (75%)
Stem cell source .53
Bone marrow 1 (5%) 2 (10%) 0
PBSCs 18 (95%) 18 (90%) 20 (100%)
Sex mismatch 10 (53%) 10 (50%) 11 (55%) 1
Conditioning .58
Myeloablative 9 (47%) 11 (55%) 13 (65%)
Reduced intensity 10 (53%) 9 (45%) 7 (35%)
GVHD prophylaxis .06
Including sirolimus 6 (32%) 9 (45%) 16 (80%)
Tacrolimus-based without
sirolimus
7 (37%) 10 (50%) 4 (20%)
Other 6 (32%) 1 (5%) 0
Gut grade
3 5 (26%)
4 14 (74%)
Skin grade
3 20 (100%)
Overall grade
2 0 20 (100%)
3 14 (74%) 0
4 5 (26%) 0
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous
leukemia; MDS, myelodysplastic syndrome; CLL, chronic lymphocytic
leukemia; PLL, prolymphocytic leukemia; CML, chronic myelogenous
leukemia; CMML, chronic myelomonocytic leukemia; CTCL, cutaneous
T cell lymphoma; NHL, non-Hodgkin lymphoma; MF, myelofibrosis; Tac,
tacrolimus; rapa, rapamycin; NA, not applicable.
*NHL includes NHL with MDS.
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of the 59 patients had blood samples collected after day
100 of HSCT; most of the samples were collected
within the first 50 days after HSCT (74% in the gut
group, 85% in the skin group, and 70% in the control
group).Surface Expression of a4b7 Integrin and CCR9
on Peripheral T Cell Subsets following HSCT in
Relation to the Development of aGVHD
Flow cytometry analysis of surface expression of
a4b7 integrin and CCR9 on peripheral T cell subsets(Table 2) showed significant up-regulation of expres-
sion of a4b7 integrin on all studied peripheral T cell
populations in the gut group compared with both the
control and skin groups, as measured by the absolute
cell count (cells/mL) and the percentage of lympho-
cytes. Permutation testing revealed that the T cell sub-
sets exhibiting the most significant up-regulation of
a4b7 integrin expression in the gut group were the
memory T cells (CD451, CD31, and CD45RO1) in
both the CD41 and CD81 cell populations. The me-
dian expression level of absolute memory CD41
a4b71 T cells was 2.81 cells/mL in the gut group,
0.28 cell/mL in the control group (P 5 .001), and
0.13 cell/mL in the skin group (P\ .0001). When an-
alyzed according to percent lymphocytes, in the gut
group a median of 0.67% of lymphocytes displayed
the memory CD41 a4b71 phenotype, compared
with only 0.033% in the control group (P\ .0001)
and 0.03% in the skin group (P\ .0001). For CD81
T cells, the median expression level of absolute mem-
ory CD81 a4b71 T cells was 1.63 cells/mL in the gut
group, 0.04 cell/mL in the control (P \ .0001), and
0.021 cell/mL in the skin group (P\ .0001). Analysis
by relative expression revealed that in the gut group,
a median of 0.53% of lymphocytes displayed the mem-
ory CD81 a4b71 phenotype, compared with only
0.004% in the control group (P \ .0001) and
0.009% in the skin group (P\ .0001). Figure 1 illus-
trates the results of the analyses of a4b7 integrin ex-
pression on CD41 and CD81 memory T cells, and
Figure 2 shows representative histograms. Because
there was heterogeneity in the timing of sample collec-
tion, we investigated whether time afterHSCTor time
before GVHD symptoms affected the expression of
a4b7 integrin in the memory subsets. As shown in
Table 3, there was no significant effect of the timing
of sample collection on the expression of a4b7 integrin
in either the gut group or the skin group.
Using the recursive partitioning method and
ROC, we proposed cutoff values of 1 cell/mL and 0.5
cell/mL and applied them to the subsets of memory
CD41 a4b71 T cells and CD81 a4b71 T cells, re-
spectively (Table 4). Using these cutoff values, 79%
of patients in the gut group had $ 1 cell/mL with the
absolute memory CD41 a4b71 phenotype, compared
with 10% in both the control and skin groups
(P 5 .00002), indicating 79% sensitivity and 90%
specificity. Similarly, 74% of patients in the gut group
had $ 0.5 cell/mL with the absolute memory CD81
a4b71 phenotype, compared with 5% in the control
group (P 5 .00001) and 10% in the skin group
(P 5 .00007), indicating 74% sensitivity and a 95%
specificity.
In contrast to the significant differences observed
in a4b7 integrin expression among the 3 groups, the
only T cell subset that exhibited a significant difference
in CCR9 expression for the gut group relative to both
Table 2. Surface Expression of a4b7 Integrin and CCR9 on Various Peripheral T Cell Subsets, Median (Range)
P value
Phenotype Control (n 5 20) Skin (n 5 20) Gut (n 5 19) C vs S* C vs G* S vs G* C vs S† C vs G† S vs G†
Abs CD4 memory a4b7 0.28 (0-3.1) 0.13 (0-1.67) 2.81 (0.13-48.4) .11 <.0001 <.0001 .88 .001 <.0001
Abs CD8 memory a4b7 0.040 (0-3.3) 0.021 (0-5.25) 1.63 (0-57.0) .51 <.0001 <.0001 1.00 <.0001 <.0001
% CD4 memory a4b7 0.033 (0-0.45) 0.030 (0-0.25) 0.67 (0.02-3.31) .99 <.0001 <.0001 1.00 <.0001 <.0001
% CD8 memory a4b7 0.004 (0-0.13) 0.009 (0-0.49) 0.53 (0-13.7) .69 <.0001 <.0001 1.00 <.0001 <.0001
Abs CD4 naı¨ve a4b7 0.028 (0-0.46) 0.021 (0-0.29) 0.13 (0-8.33) .37 .0014 <.0001 1.00 .01 .008
Abs CD8 naı¨ve a4b7 0.069 (0-4.35) 0.017 (0-4.51) 0.78 (0-12.8) .13 <.0001 <.0001 1.00 .01 <.0001
% CD4 naı¨ve a4b7 0.005 (0-0.044) 0.004 (0-0.086) 0.03 (0-1.10) .95 <.0001 .001 1.00 .002 .05
% CD8 naı¨ve a4b7 0.010 (0-0.092) 0.005 (0-0.42) 0.30 (0-4.56) .60 <.0001 <.0001 1.00 <.0001 <.0001
Abs CD4 memory CCR9 0.30 (0.05-10.2) 0.22 (0-23.2) 2.23 (0.03-38.8) .70 .08 .11 1.00 .57 .70
Abs CD8 memory CCR9 0.17 (0.007-6.30) 0.23 (0.009-1.56) 0.42 (0-38.9) .35 .06 .13 1.00 .34 .61
% CD4 memory CCR9 0.04 (0.004-1.10) 0.087 (0-11.2) 0.30 (0.007-9.14) .29 .050 .67 .75 .17 1.00
% CD8 memory CCR9 0.017 (0.002-0.33) 0.056 (0.008-0.40) 0.17 (0-2.70) .007 .032 .52 .51 .006 .78
Abs CD4 naı¨ve CCR9 0.12 (0-2.47) 0.065 (0-14.1) 0.31 (0-1.89) .92 .30 .81 1.00 1.00 1.00
Abs CD8 naı¨ve CCR9 0.12 (0-8.82) 0.054 (0-1.01) 0.15 (0-15.7) .07 .56 .04 .94 1.00 .60
% CD4 naı¨ve CCR9 0.009 (0-0.43) 0.007 (0-4.65) 0.026 (0-3.53) .38 .21 .86 .58 1.00 1.00
% CD8 naı¨ve CCR9 0.02 (0-0.21) 0.017 (0-0.10) 0.032 (0-1.91) .97 .44 .46 1.00 .71 .52
Abs indicates absolute number of cells/mL; %, percent lymphocytes; C, control; S, skin; G, gut.
Note. Significantly different comparisons are in bold.
*From the exact WRS test.
†From the permutation test.
1070 Biol Blood Marrow Transplant 15:1066-1076, 2009Y.-B. Chen et al.the skin and control groups was the memory CD81
population when measured as percent lymphocytes.
Surface expression of both CLA and CCR10 also
were analyzed in these T cell populations, because
both are considered specific mediators of lymphocyte
trafficking in the skin. No significant differences in
their expression was found in the 3 patient groups or
in any of the peripheral T cell populations studied
(data not shown).Absolute Number of Peripheral Blood Memory
CD4+ T-cells Expressing α4β7 Integrin
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Figure 1. Expression of a4b7 integrin on memory CD41 and CD81 T cells
Expression of a4b7 integrin (% lymphocytes) on memory CD41 T cells. C, Exp
sion of a4b7 integrin (% lymphocytes) onmemory CD81T cells. All values show
from permutation testing are listed in the text and in Table 2.We then performed a multivariable logistic regres-
sion analysis for each T cell subset to explore whether
surface expression of a4b7 integrin and CCR9 were
confounded by clinical characteristics, such as patient
age, donor type, conditioning regimen, recipient–
donor sex mismatch, and GVHD prophylaxis regimen
(sirolimus-containing or not). After adjusting for these
clinical characteristics, the absolute number of mem-
ory CD41 and CD81 a4b71, percent memory% of Peripheral Blood Memory CD4+ T-cells
Expressing α4β7 Integrin
0.67%
0.03%0.03%0.00%
0.50%
1.00%
1.50%
2.00%
2.50%
3.00%
3.50%
CONTROL SKIN GUT
% of Peripheral Blood Memory CD8+ T-cells
Expressing α4β7 Integrin
0.00% 0.01%
0.53%
0.00%
1.00%
2.00%
3.00%
4.00%
5.00%
CONTROL SKIN GUT
. A, Expression of a4b7 integrin (cells/mL) on memory CD41 T cells. B,
ression of a4b7 integrin (cells/mL) on memory CD81 T cells. D, Expres-
n aremedian values. P values from comparisons between groups derived
Figure 2. Expression of a4b7 integrin on peripheral blood T cell subsets in patients from the control, skin, and gut groups. Thawed mononuclear cells
were analyzed for cell surface expression of CD45RO (y-axis) and a4b7 integrin (x-axis). Plots are gated on CD31 lymphocytes based on forward and
side scatter and CD3 staining. The numbers indicate the percentage of CD31 lymphocytes for each quadrant. These values are representative patients
from within each patient group.
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a4b71, percent naı¨ve CD41 and CD81 a4b71, and
percent memory CD81 CCR91 T cells in the gut
group remained significantly associated with develop-
ment of intestinal aGVHD (P\ .05) (Table 5). The
absolute number of naı¨ve CD81 a4b71 T cells was
borderline significant (P5 .06). This finding was con-
sistent with the results of univariate analysis. In con-
trast, none of these phenotypes were predictive for
cutaneous aGVHD (Table 5).
Spearman Correlation
We carried out Spearman correlation analysis to
investigate a possible association between the naı¨ve
and memory CD41 and CD81 phenotypes for a4b7
expression in patients with intestinal aGVHD. As
shown in Table 6, a strong correlation was found be-
tween the CD41 and CD81 memory and naı¨ve cells
that expressed a4b7 integrin. Indeed, the association
between memory CD41 and CD81 T cells was quite
close (correlation coefficient, r 5 0.85; P \ .0001).
Similar findings were found when this analysis was car-
ried out with measurements of percent lymphocytes
(r 5 0.81; P\ .0001) (data not shown).Table 3. Correlation between Expression of a4b7 Integrin on
Activated T Cell Subsets with Time from Transplantation or
Time before Onset of aGVHD Symptoms in Patients in the
Gut and Skin Groups
Gut Skin
Potential Correlation r P r P
Expression of a4b7 on memory CD4+ T cells
and time before onset of aGVHD
0.22 .37 0.29 .22
Expression of a4b7 on memory CD8+ T cells
and time before onset of aGVHD
0.3 .21 0.27 .24
Expression of a4b7 on memory CD4+ T cells
and time from HSCT to sample collection
0.11 .64 0.3 .2
Expression of a4b7 on memory CD8+ T cells
and time from HSCT to sample collection
0.23 .34 0.33 .15
aGVHD indicates acute graft-verus-host disease.Influence of Clinical Factors on a4b7 Integrin
and CCR9 Expression
We examined memory CD41 and CD81 T cell
surface expression of a4b7 integrin in relation to the
intensity of the conditioning regimen (MA vs RIC),
donor type (MRD vs MUD), GVHD prophylaxis reg-
imen (sirolimus-containing vs not), and recipient age
(\50 years vs $ 50 years). The results for the control
and skin groups were pooled and compared with the
results for the gut group. For recipient age, in the
gut group, the median expression level of absolute
CD41 memory a4b7 was 3.77 for age \ 50 years
and 1.7 for age$ 50 years (P5 .90 using permutation
testing). In the control and skin combined group, the
median level was 0.3 for age\ 50 years and 0.09 for
age$ 50 years (P5 .88). Similarly, intensity of condi-
tioning regimen, donor type, and GVHD prophylaxis
regimen showed no influence on memory T cell sur-
face expression of a4b7 integrin and CCR9.
We performed linear regression analysis to further
examine the differences in expression level between the
gut group and the other groups in the presence of pa-
tient age, conditioning regimen, donor type, GVHDTable 4. ProposedCutoff Values forMemoryCD4+a4b7+ and
Memory CD8+ a4b7+ T Cells
ORGAN
CONTROL GUT SKIN Cvs S C vs G S vs G
CD4+ (cells/ul)
<1 18 (90%) 4 (21%) 18 (90%) 1 .00002 .00002
>51 2 (10%) 15 (79%) 2 (10%)
CD8+ (cells/ul)
<0.5 19 (95) 5 (26%) 18 (90) 1 .00001 .00007
>50.5 1 (5%) 14 (74%) 2 (10%)
C indicates control; S, skin; G, gut.
Note. Using the recursive partitioning method and ROC, cutoff values of
1 cell/mL and 0.5 cell/mL were applied to the subsets of memory CD4+
a4b7+ T cells andmemoryCD8+ a4b7+ T cells, respectively. P values are
2-way comparisons.
Table 5. Multivariable Logistic RegressionAnalysis for EachT
Cell Subset
Gut Skin
OR (95% CI) P OR (95% CI) P
Abs CD4 memory a4b7 3.37 (1.56-7.28) .002 0.73 (0.46-1.15) .17
Abs CD8 memory a4b7 1.91 (1.24-2.94) .004 0.77 (0.5-1.18) .23
% CD4 memory a4b7 3.96 (1.84-8.55) .0004 0.98 (0.54-1.76) .93
% CD8 memory a4b7 2.91 (1.52-5.58) .001 0.94 (0.54-1.63) .83
Abs CD4 naive a4b7 1.97 (1.17-3.34) .01 0.97 (0.6-1.55) .89
Abs CD8 naı¨ve a4b7 1.51 (0.99-2.29) .06 0.70 (0.45-1.09) .12
% CD4 naı¨ve a4b7 4.08 (1.67-9.95) .002 1.93 (0.89-4.2) .10
% CD8 naı¨ve a4b7 2.2 (1.25-3.89) .007 0.91 (0.53-1.58) .75
Abs CD4 memory CCR9 1.39 (0.96-2.02) .08 1.09 (0.76-1.55) .64
Abs CD8 memory CCR9 1.50 (0.97-2.34) .07 1.07 (0.68-1.68) .76
% CD4 memory CCR9 1.64 (1.1-2.47) .02 1.47 (0.99-2.18) .05
% CD8 memory CCR9 2.49 (1.35-4.59) .003 1.63 (0.93-2.86) .09
Abs CD4 naı¨ve CCR9 1.06 (0.77-1.47) .71 1.07 (0.78-1.47) .66
Abs CD8 naı¨ve CCR9 1.01 (0.66-1.55) .97 0.72 (0.46-1.12) .15
% CD4 naı¨ve CCR9 1.17 (0.78-1.74) .44 1.36 (0.93-1.98) .11
% CD8 naive CCR9 1.53 (0.8-2.92) .19 0.82 (0.43-1.57) .55
OR indicates odds ratio with the control group as the reference group;
CI, confidence interval; Abs, absolute number of cells/mL; %, percent
lymphocytes.
Note. Clinical characteristics adjusted for patient age, donor type, con-
ditioning regimen, GVHD prophylaxis (sirolimus-containing or not), and
recipient–donor sex mismatch.
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match. The development of intestinal aGVHD con-
tinued to be the most significant factor affecting
expression of a4b7 integrin in both memory CD81
and CD41 T cells (P\ .0001) (data not shown).
We reviewed patient records from the gut group
for any evidence of common infections of the gastro-
intestinal tract after HSCT, specifically adenovirus,
cytomegalovirus (CMV), and Clostridium difficile
(Cdiff). No patients in the gut group exhibited evi-
dence of adenovirus or direct intestinal infection
with CMV. Three patients were found to have blood
CMV reactivation, as detected by blood antigen or
polymerase chain reaction–based assays within 1
month after onset of aGVHD symptoms, none of
which progressed to intestinal disease. Two patients
were found to have evidence of Cdiff infection, as de-
tected by toxin assays, within 1 month after symptom
onset. Neither CMV nor Cdiff infection was foundTable 6. Spearman Correlation for Measurements of Abso-
lute Number of Cells per mL Expressing a4b7 Integrin in
Memory and Naı¨ve CD4+ and CD8+ T Cell Populations
Memory CD4+ Memory CD8+ Naı¨ve CD4+ Naı¨ve CD8+
Memory CD4+ 22 r 5 0.85 r 5 0.70 r 5 0.81
P < .0001 P 5 .001 P < .0001
Memory CD8+ r 5 0.85 22 r 5 0.54 r 5 0.78
P < .0001 P 5 .018 P < .0001
Naı¨ve CD4+ r 5 0.70 r 5 0.54 22 r 5 0.59
P 5 .001 P 5 .018 P 5 .008
Naı¨ve CD8+ r 5 0.81 r 5 0.78 r 5 0.59 22
P < .0001 P < .0001 P 5 .008to have an effect on a4b7 integrin expression (data
not shown).
Expression of a4b7 Integrin in Intestinal Biopsy
Specimens from Patients with aGVHD
Sigmoid biopsy specimens were obtained from 17
of the 19 patients in the gut group at the time of the ini-
tial diagnosis of aGVHD. All specimens exhibited
pathological findings consistent with aGVHD. Suffi-
cient paraffin-embedded samples for all 17 patients
were available for immunohistochemical staining. All
17 biopsy specimens showed areas of a4b71 mononu-
clear cells infiltrating within the lamina propria in
areas of active aGVHD; however, the staining was het-
erogeneous and patchy in distribution. Representative
areas of infiltration are shown in Figure 3A and B. In-
terestingly, the highest concentration of a4b7 integ-
rin–expressing cells was found as aggregates within
small mucosal blood vessels (Figure 3C-E). Intestinal
biopsy specimens from patients in both the skin and
control groups had not been performed, given the
lack of GI symptoms in these patients. We found sev-
eral intestinal biopsy specimens obtained from patients
after HSCT who did not have aGVHD in our pathol-
ogy archives, and performed immunohistochemical
staining on them. Mucosal blood vessels in these bi-
opsy specimens did not exhibit the same aggregation
of a4b71 mononuclear cells found in specimens from
patients in the gut group (Figure 3F and G).DISCUSSION
Recently, several murine models have illustrated
that lymphocyte migration after HSCT involves
sequential trafficking of naı¨ve donor T cells to host
secondary lymphoid tissue, followed by specific infil-
tration into target organs to cause aGVHD. Data
from these models suggest that the initial afferent
phase of this response occurs within the first few hours
to days after allogeneic HSCT and well before clinical
manifestations of aGVHD appear [29,30]. Therefore,
defining the specific adhesion molecules involved in
the lymphocyte trafficking of either the afferent or ef-
ferent phase of aGVHDmay provide novel opportuni-
ties for the monitoring, prophylaxis, and treatment of
aGVHD after HSCT; for instance, reliable prediction
of the development of intestinal aGVHD may allow
institution of specific preemptive therapy or a different
schedule of immunosuppression withdrawal.
In this retrospective case-controlled study, we an-
alyzed the surface expression of both a4b7 integrin and
CCR9 on various T cell subsets from 3 groups of pa-
tients after HSCT (no aGVHD, skin-predominant
aGVHD, and gut-predominant aGVHD) from blood
samples obtained before the onset of aGVHD symp-
toms. Our primary aim was to determine whether
Figure 3. Expression of a4b7 integrin in sigmoid biopsy specimens from patients with intestinal aGVHD. Immunohistochemical staining for a4b7 in-
tegrin (brown stain) shows patchy expression of a4b7 integrin on mononuclear cells within the lamina propria (A and B) and as aggregates within small
mucosal blood vessels (C, D, and E). Specimens from patients after HSCTwho did not have intestinal aGVHD do not show such staining (F and G). See
the Immunohistochemistry section of the text for complete descriptions of techniques and image acquisition information.
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eral blood T cells is correlated with the subsequent de-
velopment of intestinal aGVHD. Our results show
that a4b7 integrin was significantly up-regulated on
both memory and naı¨ve T cells, most strikingly in
thememory subsets in patients whowent on to develop
intestinal aGVHD. Indeed, expression on CD41 and
CD81 memory T cell subsets was at least 10-fold
higher in patients with intestinal aGVHD than in
those with cutaneous or no aGVHD. In contrast,
CCR9 expression was less useful, not clearly different
between the 3 groups. A recent study inmice suggested
that CCR9 expression is a marker of immature den-
dritic cells, which seem to induce tolerance and to pro-
tect against GVHD implying that the overall role of
CCR9 remains unclear [31]. We also analyzed CLA
and CCR10 expression in the present study, because
these are considered specific mediators of lymphocyte
trafficking to the skin, but we found no significant dif-
ferences in the expression of these molecules in the 3
patient groups.
After correction for multiple comparisons, a4b7
integrin expression remained significantly increased
on memory T cells in both the CD41 and CD81 sub-sets from patients in the gut group. In adjusted multi-
variable logistic regression analysis, these phenotypes
were predictive for the development of intestinal
aGVHD using samples obtained a median of 14 days
before the onset of aGVHD symptoms. Analysis of
the correlation between the subsets demonstrated
that expression of a4b7 integrin on memory CD41
and CD81 T cells had a strong association with the
other phenotypes, suggesting that the CD41 or
CD81 CD45RO1 a4b71 phenotype could be consid-
ered for evaluation as a potential biomarker for intes-
tinal aGVHD in future investigations. Based on our
results, we propose a cutoff value of 1 cell/mL for abso-
lute memory CD41 a4b71 T cells and 0.5 cell/mL for
absolute memory CD81 a4b71 T cells, to maximize
specificity.
Given that this was a retrospective analysis, there
was significant heterogeneity in terms of patient char-
acteristics and the timing of sample collection. But
even with such variation in donor source, conditioning
regimen, recipient age, and GVHD prophylaxis regi-
men, a significant up-regulation of a4b7 integrin ex-
pression on activated T cells was observed in patients
who later developed intestinal aGVHD. This finding
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immunologic responses should continue to be driven
by the same mediators regardless of such clinical char-
acteristics. Although the timing of the sample collec-
tion (a median of 14 days before the onset of
aGVHD symptoms; most within 30 days) may seem
relatively remote from the onset of clinical aGVHD,
it is consistent with the previously described murine
models showing an early initial activation phase with
trafficking to secondary lymphoid tissue, followed by
delayed clinical manifestations [29,30]. Clearly, the
true association and predictive value of measuring
a4b7 integrin expression can be defined only in a pro-
spective trial involving serial samples from patients af-
ter HSCT; such a study is underway at our institution.
Another possibility is that before HSCT, stem cell do-
nors have naturally higher levels of T cell expression of
a4b7 integrin, which may predispose recipients to de-
velop intestinal GVHD. No pre-HSCT donor sam-
ples were available for this cohort in the present
study, although such a study also is underway at our in-
stitution.
The histological findings of intestinal aGVHD
range from mild to severe. Mild cases show spotty ap-
optosis with focal infiltrates of lymphocytes, plasma
cells, or eosinophils, whereas severe cases show diffuse
crypt cell necrosis [32,33]. Mediators of intestinal lym-
phocyte trafficking have never been analyzed in patho-
logical specimens of human patients with aGVHD. In
this study, all evaluable rectal biopsy specimens consis-
tent with intestinal GVHD exhibited evidence of
a4b71 mononuclear cells located within small termi-
nal mucosal blood vessels, which may represent an
early phase of lymphocyte trafficking. These cells
were not observed in intestinal tissue from healthy pa-
tients or from biopsy specimens obtained from pa-
tients after HSCT who did not have intestinal
aGVHD. These data support the idea that the in-
creased expression of a4b7 integrin on peripheral
bloodT cells mirrors what is occurring in the intestine,
the principle target tissue.
To date, very few human studies have investigated
lymphocyte trafficking molecules associated with
aGVHD. One such study found that patients with
aGVHD had increased expression of certain adhesion
molecules, such as ICAM-1 and VLA-4, on their pe-
ripheral blood lymphocytes compared with controls
who had undergone HSCT without developing
aGVHD [34]. Three recent studies have analyzed spe-
cific chemokines and their receptors in the setting of
aGVHD. One of these studies suggested a correlation
between higher levels of CCR71 CD41 T cells in do-
nor grafts and the incidence and severity of aGVHD
[35]. Another study that used PCR to analyze chemo-
kine receptor expression on peripheral blood lympho-
cytes found a correlation between up-regulation of
CCR5, CXCR3, CCR1, and CCR2 with episodes ofaGVHD [36]. Most recently, a prospective analysis
of 34 patients after HSCT showed a 2-fold up-regula-
tion in serum levels of chemokine CXCL10 in patients
with aGVHD relative to control patients. As part of
their analysis, the investigators also analyzed CLA
and b7 integrin expression among activated CD41
and CD81 T cell subsets and found no significant
up-regulation of these molecules in patients with
aGVHD [37]. But that study included only 34 patients
and, unlike our study, did not stratify patients based on
the specific organ of involvement.
Although to date no human studies have inves-
tigated specific mediators of intestinal lymphocyte
trafficking in aGVHD of the intestine, several experi-
ments have been performed in mouse models, with
mixed conclusions. Murai et al. [38] reported that
Peyer’s patch–deficient host mice did not develop
aGVHD after bone marrow transplantation, and that
blocking access to Peyer’s patch via a monoclonal an-
tibody (mAb) against MAdCAM-1 protected mice
from aGVHD. In separate studies, investigators from
Memorial Sloan Kettering found that purging donor
cells of a4b71 T cells or using a selective b7 integrin
knockout strain as the source of donor stem cells re-
sulted in significant reductions in the overall inci-
dence, clinical and histological manifestations, and
mortality from intestinal aGVHD [39,40]. In contrast,
another study suggested that knockout of b7 was insuf-
ficient to modify intestinal aGVHD, and that addi-
tional knockout of L-selectin was required to bring
about a significant reduction in aGVHD [41]. Beilhack
et al. [8] performed several experiments in murine
models in which entry to different secondary lymphoid
tissues was restricted by the use of mAb directed
against specific mediators of lymphocyte trafficking.
They found that blocking entry to specific secondary
lymphoid organs (either peripheral lymph nodes or
Peyer’s patches) had no effect on aGVHD, suggesting
redundancy in secondary lymphoid tissue compart-
ments [8]. Most recently, Anderson et al. [42] investi-
gated the importance of secondary lymphoid tissue
in aGVHD initiation using mice deficient in either
CD62L or CCR7 or using peripheral lymph node–
and Peyer’s patch–deficient mice as recipients, and
found that clinically significant GVHD developed in
both of these settings.
Drawing general conclusions from these individual
studies is difficult, because they used different mouse
donor–recipient combinations and different models
of HSCT. Overall, the results support the theory
that aGVHD is initiated by allogeneic activation in
secondary lymphoid tissue, with induction of a specific
trafficking phenotype dependent on the location of
the secondary lymphoid tissue [8]. Whether blocking
access to certain secondary lymphoid tissues has a clin-
ically significant effect on aGVHD is unclear, how-
ever. In the murine studies that showed a benefit of
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incidence of intestinal aGVHD was not dramatically
reduced; rather, aGVHD seemed to be delayed and
decreased in severity, which translated into less mor-
bidity and mortality. These benefits need to be inter-
preted in the proper context, given that antibiotics,
immunosuppressive therapy, and other standard sup-
portive care measures of clinical care after HSCT are
not usually included in mouse experiments. Neverthe-
less, inhibiting early trafficking to GALT may allow
time for the intestine to heal after injury from the con-
ditioning regimen, which may result in decreased in-
flammatory cytokine and chemokine production,
leading to amoderation of the allorecognition reaction
when it does occur [43,44].
In summary, our data demonstrate that up-regula-
tion of a4b7 integrin on the surface of activated T cells
appears to be correlated with the subsequent develop-
ment of intestinal aGVHD in patients after HSCT.
These data need to be validated in a prospective study,
which is ongoing at our institution. This prospective
study also will allow us to better analyze the effect of
infections and other clinical factors, as well as to in-
clude patients who develop lower grades of intestinal
GVHD. Furthermore, collection of samples at stan-
dard prospective times both before and after the onset
of aGVHD will indicate whether a specific time after
HSCT or interval before the onset of symptoms is im-
portant and demonstrate whether expression level cor-
relates with treatment response. Most importantly,
a prospective analysis will confirm whether expression
of a4b7 integrin on memory T cells can be a predictive
biomarker for intestinal aGVHD. Having a predictive
biomarker for intestinal aGVHD should prove very
valuable in clinical practice, aiding the delivery of pre-
emptive targeted therapy before the onset of clinical
manifestations or refinement of the schedule of immu-
nosuppression withdrawal. In addition, identification
of the adhesion molecules involved in intestinal
aGVHD can provide novel targets for more specific
therapy. Such therapies are currently under study for
the treatment of inflammatory bowel disease [45],
and these studies support the further evaluation of
these agents in intestinal aGVHD.ACKNOWLEDGMENTS
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